MedTrace Logo

Urdu Version of Menopause-specific Quality of Life Scale

NCT05913648 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 290

Last updated 2024-03-05

No results posted yet for this study

Summary

Menopause is accompanied by a spectrum of symptoms that are frequently related to hormonal changes. Menopause and its symptoms frequently have an impact on postmenopausal women's Quality of Life. There is a need for culturally adapted screening tool to aid healthcare professionals or clinicians to screen the symptoms of menopausal women, so the aim of this study is to translate the Menopause specific quality of life (MENQOL) into Urdu and to find the reliability and validity of the translated version Menopause specific quality of life in menopausal women.

Conditions

Interventions

OTHER

Tool Translation

The Data Collection procedure will be done in two phases. The first phase will revolve around the translation of the instrument. Firstly the tool will be translated into Urdu with the help of two professional translators and then it will be back-translated into English to cross-check the clarity of the text. The translation will focus more on the context and understanding of the text rather than literal word-to-word meanings. The translation will be done according to the WHO guidelines. The Urdu version of MENQOL will be used to assess content validity on menopausal women.

Sponsors & Collaborators

  • Riphah International University

    lead OTHER

Principal Investigators

  • Huma Riaz, PHD* · Riphah International University

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-15
Primary Completion
2023-10-30
Completion
2023-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05913648 on ClinicalTrials.gov